Neuroendocrine gastroenteropancreatic tumors: 11 Years of clinical experience

International Journal of Medicine, Biology and the Environment

Volumn 29, Issue 2, 2001, Pages 129-141

  Cirillo, Fernando ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Alpha interferon; Carcinoid tumors; Chemotherapy; Endocrine pancreatic tumors; Immunohistochemistry; Neuroendocrine tumors; Somatostatin analogues; Somatostatin receptors; Surgical treatment; Tumor markers

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ALPHA2B INTERFERON; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CHROMOGRANIN A; CISPLATIN; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IODINE 131; MONOCLONAL ANTIBODY KI 67; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; VAPREOTIDE;

ADOLESCENT; ADULT; AGED; ANALYTICAL EQUIPMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOID; CELL PROLIFERATION; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DRUG RESPONSE; ECHOGRAPHY; FEMALE; GASTROINTESTINAL TUMOR; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ISLET CELL TUMOR; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; SIDE EFFECT; TACHYPHYLAXIS;

EID: 0035412544     PISSN: 1128935X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Pearse, A.G.E., Takor, T. Neuroendocrine embriology and APUD concept. Clin Endocrinol 5, 229-37 (1976)
2. Schein, P.S., De Lellis, R.P., Kahn, C.R., Gorden, P., Kraft, A.R. Current concepts and management of islet cell tumor. Ann Intern Med 79, 239-45 (1973)
3. Chiti, A., Briganti, V., Fanti, S., Monetti, N., Masi, R., Bombardieri, E. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. Q J Nucl Med 44, 42-49 (2000)
4. Eriksson, B., Bergström, M., Örlefors, H., Sundin, A., Öberg, K., Långström, B. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Q J Nucl A Med 44, 68-76 (2000)
5. Seregni, E., Ferrari, L., Stivanello M., Dogliotti, L. Laboratory tests for neuroendocrine tumours. Q J Nucl Med 44, 22-41 (2000)
6. Eriksson, B., Öberg K., Stridsberg, M. Tumor markers in neuroendocrine tumors. Digestion 62(l), 33-38 (2000)
7. Arnold, R., Simon, B., Wied, M. Treatment of neuroendocrine GEP tumours with somatostatin analogues. A review. Digestion 62(1), 84-91 (2000)
8. Öberg, K. Interferon in the management of neuroendocrine GEP-tumours. A review, Digestion 62(l), 92-97 (2000)
9. Solcia, E., Klöppel, G., Sobin, L.H. Histological typing of endocrine tumours.WHO, Springer-Verlag Berlin Heidelberg (2000)
10. Rindi, G., Capella, C., Solcia, E. Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropncreatic tract. Q J Nucl Med 44, 13-21 (2000)
11. Soga, J. Carcinoids of the colon and ileal region:a statistical evaluation of 363 cases collected from the literature. J Exp Clin Cancer Res 17, 139-48 (1999)
12. Soga, J. Statistical evaluation of 2001 carcinoid cases with metastases,collected from literature: a comparative study between ordinary carcinoids and atypical varieties. J Exp Clin Cancer Res 17, 3-12 (1998)
13. Soga, J. Carcinoids of the small intestine: a statistical evaluation of 1102 cases collected from the literature. J Exp Clin Cancer Res 16, 353-63 (1997)
14. Sandor, A., Modlin, I.M. A retrospective analysis of 1570 appendiceal carcinoids. Am J Gastroenterol 93, 422-28 (1998)
15. Soga, J. Carcinoids of the resctum:an evaluation of 1271 reported cases. Surg Today 27, 112-19 (1997)
16. Soga, J., Yakuwa, Y. Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res 17, 389-400 (1998)
17. Soga, J., Yakuwa, Y. The gastrinoma/Zollinger-Ellison syndrome: statistical evaluation of a Japanese series of 359 cases. J Hep Bil Pancr Surg 5, 77-85 (1998)
18. Soga, J., Yakuwa; Y. Glucagonomas/diabeticodermatogenic syndrome (DDS):a statistical evaluation of 407 reported cases. J Hep Bil Pancr Surg 5, 312-19 (1998)
19. Soga, J., Yakuwa, Y., Osaka, M. Insulinomas/Hypoglycemic syndrome:a statistical evaluation of 1085 reported cases of a Japanese series. J Exp Clin Cancer Res 17, 379-88 (1998)
20. Gerbitz, K.D., Summer, J., Schumacher, I., Arnold, H., Kraft, A., Mross, K. Enolase isoenzymes as tumour markers. J Clin Chem Clin Biochem 24, 1009-16 (1986)
21. Prinz, R.A., Marangos, P.J. Use of neurospecific enolase as a serum marker for neuroendocrine neoplasmas. Surgery 92, 887-89 (1982)
22. Prinz, R.A., Bermes, E. W. Jr, Kimmel, J.R., Marangos, P.J. Serum markers for pancreatic islet cell and intestinal carcinoid tumors: a comparison of neuron-specific enolase, β-human chorionic gonadotropin and pancreatic polypeptide. Surgery 94, 1019-23 (1983)
23. O' Connor, D.T., Deftos, L.J. Secretion of chromogranin A by peptide-producing endocrine neoplasm. N Engl J Med 314, 1145-51 (1986)
24. Eriksson, B., Arnberg, H., Oberg, K., Hellman, U., Lundqvist, G., Wernstedt, C., Wilander, E. Chromogranins-new sensitive markers for neuroendocrine tumors. Acta Oncol 28, 325-29 (1988)
25. Nobels, F.R.E., Kwekkeboom, D.J., Coopmans, W., Schoenmakers, C.H.H., Lindemans, J., De Herder, W.W., Krenning, E.P., et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the a-subunit of glycoproein hormones. J Clin Endocrinol Metab 82, 2622-28 (1997)
26. Ferrari, L., Seregni, E., Bajetta, E., Martinetti, A., Bombardieri, E. The biological characteristics of chromogranin A and its role as circulating marker in neuroendocrine tumours. Anticancer Res 19(4c), 3415-27 (1999)
27. Krudy, A.G., Doppman, J.L., Jensen, R.T. et al. Localisation of islet cell tumors by dinamic CT: comparison with plain CT, arteriography, sonography and venous sampling. Am J Roentgenol 143, 585-89 (1984)
28. Van Hoe, L., Gryspeerdt, S., Marchal, G., et al. Helical CT for the preoperative localization of islet cell tumors of the pancreas:value of arterial and parenchimal phase images. AJR 165, 1437-39 (1995)
29. Chung, M.J., Choi, B.I., Han, J.K., et al. Functioning islet cell tumor of the pancreas. Localization with dynamic spiral CT. Acta Radiol 38, 135-38 (1997)
30. Ichikawa, T., Peterson, M.S., Federle, M.P., et al. Islet cell tumor of the pancreas:biphasic CT versus MR imaging in tumor detection. Radiology 216, 163-71 (2000)
31. Van Hoe, L,, Gryspeerdt, S., Baert, A.L., et al. Functioning endocrine tumors of the pancreas: comparison of single-shot MRI and dual-phase helical CT. Eur Radiol 7, S142 (1997)
32. Rosch, T., Lightdale. C.T., Botet, J.F., et al. Localization of pancreatic endocrine tumors by endoscopiC ultrasonography. N Engl. J Med 326, 1721-26 (1992)
33. Ruszniewski, P., Amouyal, P., Amouyal, G., et al. Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinoer-Ellison syndrome. Surgery 117, 629-35 (1995)
34. Schumaher, B., Lubke, H.J., Frieling, T., et al. Prospective study on the detection Of insulinomas by endoscopiC Ultrasonography. Endoscopy 28, 273-76 (1996)
35. Lamberts, S.W.J., Krenning, E.P., Reubi, J.C. The role of somatostatin and its analogs in the diagnosis and treatment of tumours. Endocrine Rev 12, 450-82 (1991)
36. Reubi, J.C., Kvols, L., Krenning, F., Lamberts, S.W. Distribution of somatostatin receptors in normal and tumor tissue. Metabolism 39(9 suppl.2), 78-91 (1990)
37. Krenning, E.P., Kwekkeboom, D.J., Pauwels, E.K., Kvols, L.K., Reubi, J.C. Somatostatin receptor scintigraphy. In: Nuclear Medicine Annual 1-50, Raven Press, New York ( 1995)
38. Valkema, R., Steens, J., Cleton, F.J., Pauwels, E.K. The diagnostic utility of somatostatin receptor scintigraphy in oncology. J Cancer Res Clin Oncol 122, 513-32 (1996)
39. Termanini, B., Gibril, F., Reynolds, J.C., et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 112, 335-47 (1997)
40. Cadiot, G., Bonnaud, G., Lebtahi, R., et al. Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Gut 41, 107-14 (1997)
41. Lebtahi, R., Cadiot, G., Sarda, L., Daou, D., Faraggi, M., Petegnief, Y., et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 38, 853-58 (1997)
42. Chiti, A., Fanti, S., Savelli, G., Romeo, A., Bellanova, B., Rodari, M., van Graafeiland, B.J., et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastroentero-pancreatic tumours. Eur J Nucl Med 25, 1396-1403 (1998)
43. Öberg, K., Eriksson, B. Medical treatment of neuroendocrine gut and pancreatic tumors. Acta Oncol 28, 425-31 (1989)
44. Lamberts, S.W., Hofland, L.J., van Koetsveld, P.M., Reubi, J.R., Bruining, H.A., Bakker, W.H., et al. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. J Clin Endocrinol Metab 71, 566-74 (1990)
45. Falconi, M., Bonora, A., Bassi, C., Contro, C., Macucci, S., Marchiori, L., Salamini, G., Scarpa, A., Pederzoli, P. Non-functioning pancreatic endocrine tumours. In: Pancreatic tumors. Achievements and prospective (Dervenis, C.G., Bassi, C., eds), 354-61, Thieme Verlag, Stuttgart (2000)
46. Mc Entee, G.P., Nagorney, M.D., Kvols, L.K., et al. Cytoreductive hepatic surgery for neuroendocrine tumours. Surgery 108(6), 1091-96 (1990)
47. Carty, S.E., Jensen, R.T., Norton, J.A. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 112 (6), 1024-32 (1992)
48. Norton, J.A. Surgical management of carcinoid tumors: role of debulking and surgery for patients with advanced disease. Digestion 55 (3), 98-103 (1994)
49. Klotter, H.L., Ruckert, K., Kummerle, F., et al. The use of intraoperative sonographic in endocrine tumors of the pancreas. World J Surg 11, 635-41 (1987)
50. Norton, J.A., Cromack, D.T., Shawker, T.H., et al. Intraoperative ultrasonographic localization of islet cell tumors. A prospective comparison to palpation. Ann Surg 207, 160-68 (1988)
51. Cirillo, F., Bottini, A., Lima, G., Alquanti, A. Chirurgia radioguidata nel trattamento dei tumori neuroendocrini gastroenteropancreatici. Minerva Chir 55, 517-21 (2000)
52. Mazzaferro, V., Schiavo, M., Coppa J., Regalia, E., Sarli, D. Resezione chirurgica e trapianto di fegato nel trattamento delle metastasi epatiche da neoplasic neuroendocrine. In: I Tumori neuroendocrini gastroente ropancreatici. Manuale di diagnosi e trattamento (Cirillo, F. ed) third edition, 365-78, Casa Editrice Ambrosiana, Milano (2001)
53. Rougier, P., Ducreux, M. Systemic chemotherapy of advanced digestive neuroendocrine tumours. Ital J Gastroenterol Hepatol 31(2), S 202-6 (1999)
54. Moertel, G.C., Kvols, L.K., O'Connell, M.J., Rubin, J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer 68, 227-32 (1991)
55. Seitz, J.F., Perrier, H., Giovannini, M., Monges, G., Fourdan, O., Barrière, N., et al. Cancers neuroendocrines anaplasiques avancés: intérét de l'association VP16-CDDP. Bull Cancer 82, 433-44 (1995)
56. Yakendji, K., Ducreux, M., Duviliard, P., Fabri, M.C., Lasser, Ph., Armand, J.P., et al. L'efficacité de l'association etoposide (VP16) et cisplatinum (CDDP) dans les tumeurs neuroendocrines (TNE) peu différenciées d'origine digestive. Bull Cancer 82, 433 (1995)
57. Mitry, E., Baudin, E., Ducreux, M., Sabourin, J.C., Rufie, P., Aparicio, T., Lasser, P., Elias, D., Duvillard, P., Schlumberger, M., Rougier, P. Treatment of poorly differentiated neuroendocrine tumors with etoposide and cisplatin. Br J Cancer 81(8), 1351-55 (1999)
58. Cheng, P.N.M., Saltz, L.B. Failure to confirm major objective antitumor activity for streptozotocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86, 944-48 (1999)
59. Wymenga, A.N.M., Eriksson, B., Salmela, P.I., Jacobsen, M.B., Van Cutsem, E.J.D.G., Fiasse, R.H., Välimäki, M.J., De Vries, E.G.E., Öberg, K.E. Efficacy and safety of pro longed-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 17, 111-17 (1999)
60. Rubin, J., Ajani, J., Schirmer, W., Venook, A., Bukoski, R., Pommier, R., Saltz, L., Dandona, P., Anthony, L. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid sindrome. J Clin Oncol 17(2), 600-6 (1999)
61. Van Hagen, P.M., Krennin, E.P., Kwekkeboom, D.J., Reubi, J.C., Anker Lugtemburg, P.J., Lowenbera, B., et al. Somatostatin and the immune and haematopoetic system, a review. Eur J Clin Invest 24, 91-99 (1994)
62. Reubi, J.C., Horisberger, U., Laissue, J. High density of somatostatin receptors in veins surrounding human cancer tissue : role in tumor-host interaction? Int J Cancer 56, 681-88 (1994)
63. Denzler, B., Reubi, J.C. Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer 85, 188-98 (1999)
64. Gorden, P. Somatostatin and somatostatin analogue (SMS 201-995) in the treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non neoplastic disease of the gut. Ann Intern Med 110, 35-50 (1989)
65. Arnold, R., Frank, M., Kajdan, U. Management of gastroenteropancreatic endocrine tumors; the place of somatostatin analogues. Digestion 55, 107-13 (1994)
66. Saltz, L., Trochanowsky, B., Buckley, M., et al. Octreotide as an antineoplastic agent in the treatment of functional and non-functional neuro-endocrine tumors. Cancer 72, 244-48 (1993)
67. Di Bartolomeo, M., Bajetta, E., Buzzoni, R., et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. Cancer 77, 402-8 (1996)
68. Ducreux, M., Ruszniewski, P., Chayvialle, J.A., Blumberg, J., et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 95, 3276-81 (2000)
69. Cirillo, F. Medical treatment of neuroendocrine gastroenteropancreatic tumors. Med Biol Environn 25 (1), 3-7 (1997)
70. Anthony, L., Johnson, D., Hande, K., Shaff, M., Winn, S., Krozely, M., Oates, J. Somatostatin analogue phase I trial neuroendocrine neoplasms. Acta Oncol 32, 217-23 (1993)
71. . Lamberts, S.W., Pieters, G.F., Metselar, H.J., Ong, G.L., Tan, H.S., Reubi, J.C. Development of resistence to a long-acting somatostatin analogue during treatment of two patients with metastatic endocrine pancreatic tumours. Acta Endocrinol 119, 561-66 (1988)
72. Wynick, D., Anderson, J.V., Williams S.J., Bloom, S.R. Resistence of metastatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995). Clin Endocrinol 30, 385-88 (1989)
73. Pelley, R.J., Bukowski, R.M. Recent advances in systemic therapy for gastrointestinal neuroendocrine tumors. Curr Opin Oncol 11, 32-37 (1999)
74. Öberg, K. Eriksson, B., Janson, E.T. The clinical use of interferons in the management of neuroedocrine of gastroenteropancreatic tumors. Ann N Y Acad Sci 733, 471-78 (1994)
75. Frank, M., Klose, K.J., Wied, M., et al. Combination therapy with octreotide and α interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 94, 1381-87 (1999)
76. Ruszniewski, P., Malka, D. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion 62(l), 79-83 (2000)
77. 131I-metaiodobenzylguanidine (MIBG) in treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan. Q J Nucl Med 44, 88-95 (2000)
78. 111In-pentetreotide. State of the art perspectives. Q J Nucl Med 44, 88-95 (2000)
79. Otte, A., Jerman, E., Behe, M., Goetze, M., Bucher, H.C., Roser, H.W., Heppeler, A., Mueller-Brand, J., Maecke, H.R. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 24, 792-95 (1997)
80. Otte, A., Mueller-Brand, J., Dellas, S., Nitzsche, E.U., Herrmann, R., Maecke, H.R. Yittrium-90-labeled somatostatin-analogue for cancer treatment. Lancet 351, 417-18 (1998)
81. Virgolini, I, Traub, T., Leimer, M., Novotny, C., Pangeri, T., et al. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Q J Nucl Med 44, 50-58 (2000)